Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Axsome Therapeutics, Inc.
Eligible subjects must have a diagnosis of narcolepsy per the International Classification of Sleep Disorders (ICSD-3), and exhibit symptoms of both cataplexy and EDS. Subjects meeting the entry criteria will be randomized in a 1:1 ratio to receive either AXS-12 or placebo for five weeks.
Age
15–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female subjects between 15 and 75 years of age, inclusive
Primary diagnosis of narcolepsy with cataplexy
Willing and able to comply with the study requirements
You may not be if
Other clinically significant conditions potentially causing EDS
Clinically significant psychiatric disorders
Clareo Health | A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy
